Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

References

• Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–1078. doi:10.1016/j.cell.2017.08.02828886379
   PubMed Web of Science ®Google Scholar
• Hainaut P, Pfeifer GP. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179. doi:10.1101/cshperspect.a02617927503997
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400–404. doi:10.1038/nature1101722722201
   PubMed Web of Science ®Google Scholar
• Basho RK, de Melo Gagliato D, Ueno NT, et al. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016;7(47):76362–76373. doi:10.18632/oncotarget.1298727806348
   PubMedGoogle Scholar
• Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353–360. doi:10.1038/nature1114322722193
   PubMed Web of Science ®Google Scholar
• Ren J, Wang B, Li J. Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer. BMC Syst Biol. 2018;12(Suppl S8):130. doi:10.1186/s12918-018-0646-y30577793
   PubMed Web of Science ®Google Scholar
• Koçak A, Heselmeyer-Haddad K, Lischka A, et al. High levels of chromosomal copy number alterations and TP53 mutations correlate with poor outcome in younger breast cancer patients. Am J Pathol. 2020;190(8):1643–1656. doi:10.1016/j.ajpath.2020.04.01532416097
   PubMed Web of Science ®Google Scholar
• Wang D, Kon N, Lasso G, et al. Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature. 2016;538(7623):118–122. doi:10.1038/nature1975927626385
   PubMed Web of Science ®Google Scholar
• Sullivan KD, Galbraith MD, Andrysik Z, et al. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25(1):133–143. doi:10.1038/cdd.2017.17429125602
   PubMed Web of Science ®Google Scholar
• Marchenko ND, Hanel W, Li D, et al. Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding. Cell Death Differ. 2010;17(2):255–267. doi:10.1038/cdd.2009.17319927155
   PubMed Web of Science ®Google Scholar
• Parry TE. Mutagenic mechanisms in leukemia and cancer: a new concept cytosine lack could be as mutagenic as cytosine deamination. Leuk Res. 2006;30(9):1079–1083. doi:10.1016/j.leukres.2005.12.01916820204
   PubMed Web of Science ®Google Scholar
• Fernndez-Cuesta L, Oakman C, Falagan-Lotsch P, et al. Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02–98 Phase III trial. Breast Cancer Res. 2012;14(3):R70. doi:10.1186/bcr317922551440
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Zheng X, Shariati M, et al. Survival outcomes by TP53 mutation status in metastatic breast cancer. JCO Precis Oncol. 2018;2:1–5. doi:10.1200/PO.17.0024530949620
   PubMed Web of Science ®Google Scholar
• Lopez G, Costanza J, Colleoni M, et al. Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors. Int J Mol Sci. 2019;20(3):510. doi:10.3390/ijms20030510
   PubMed Web of Science ®Google Scholar
• Silwal-Pandit L, Vollan HKM, Chin S-F, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20(13):3569–3580. doi:10.1158/1078-0432.CCR-13-294324803582
   PubMed Web of Science ®Google Scholar
• Darb-Esfahani S, Denkert C, Stenzinger A, et al. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget. 2016;7(42):67686–67698. doi:10.18632/oncotarget.1189127611952
   PubMedGoogle Scholar
• Luo Y, Huang W, Zhang H, et al. Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer. Oncol Lett. 2018;15(5):6161–6170. doi:10.3892/ol.2018.810429616097
   PubMed Web of Science ®Google Scholar
• Pileczki V, Pop L, Braicu C, et al. Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells. Onco Targets Ther. 2016;9:6921–6933. doi:10.2147/OTT.S11071927956838
   PubMed Web of Science ®Google Scholar
• Li J-P, Zhang X-M, Zhang Z, et al. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine. 2019;98(18):e15449. doi:10.1097/MD.000000000001544931045815
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256. doi:10.5858/arpa.2013-0953-SA24099077
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795. doi:10.1200/JCO.2009.25.652920404251
   PubMed Web of Science ®Google Scholar
• Brandão M, Maurer C, Ziegelmann PK, et al. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open. 2020;5(4):e000842. doi:10.1136/esmoopen-2020-00084232847835
   PubMed Web of Science ®Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555. doi:10.1038/nbt.352027018799
   PubMed Web of Science ®Google Scholar
• Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–219. doi:10.1038/nbt.251423396013
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Zhang G, Wang Y, Chen B, et al. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Ann Transl Med. 2019;7(8):179. doi:10.21037/atm.2019.04.2331168460
   PubMed Web of Science ®Google Scholar
• Rossi G, Mu Z, Rademaker AW, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res. 2018;24(3):560–568. doi:10.1158/1078-0432.CCR-17-209229180605
   PubMed Web of Science ®Google Scholar
• Tao Z, Li T, Feng Z, et al. Characterizations of cancer gene mutations in Chinese metastatic breast cancer patients. Front Oncol. 2020;10:1023. doi:10.3389/fonc.2020.0102332695676
   PubMed Web of Science ®Google Scholar
• Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33(20):2254–2261. doi:10.1200/JCO.2014.57.134925964252
   PubMed Web of Science ®Google Scholar
• Olivier M, Langer A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157–1167. doi:10.1158/1078-0432.CCR-05-102916489069
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu F, Wang Y, et al. Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. Oncol Lett. 2019;18(3):3159–3169. doi:10.3892/ol.2019.1062531452792
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MIW, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157–2165. doi:10.1038/sj.onc.121030217401424
   PubMed Web of Science ®Google Scholar
• Boettcher S, Miller PG, Sharma R, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599–604. doi:10.1126/science.aax364931395785
   PubMed Web of Science ®Google Scholar
• Shahbandi A, Jackson JG. Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity. NPJ Precis Oncol. 2019;3(1):1. doi:10.1038/s41698-018-0074-x30623031
   PubMed Web of Science ®Google Scholar
• Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381–1387. doi:10.1038/s41588-018-0204-y30224644
   PubMed Web of Science ®Google Scholar
• Terada K, Yamaguchi H, Ueki T, et al. Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. Ann Hematol. 2018;97(1):51–61. doi:10.1007/s00277-017-3143-228980058
   PubMed Web of Science ®Google Scholar
• Gencel-Augusto J, Lozano G. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev. 2020;34(17–18):1128–1146. doi:10.1101/gad.340976.12032873579
   PubMed Web of Science ®Google Scholar
• Muscolini M, Montagni E, Caristi S, et al. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle. 2009;8(20):3396–3405. doi:10.4161/cc.8.20.991019806023
   PubMed Web of Science ®Google Scholar
• Jackson JG, Pant V, Li Q, et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012;21(6):793–806. doi:10.1016/j.ccr.2012.04.02722698404
   PubMed Web of Science ®Google Scholar
• Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin−cyclophosphamide regimen. PLoS Med. 2007;4(3):e90. doi:10.1371/journal.pmed.004009017388661
   PubMed Web of Science ®Google Scholar
• Bertheau P, Espié M, Turpin E, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology. 2008;75(2):132–139. doi:10.1159/00012385118544968
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised Phase 3 trial. Lancet Oncol. 2011;12(6):527–539. doi:10.1016/S1470-2045(11)70094-821570352
   PubMed Web of Science ®Google Scholar
• Kai K, Nishimura R, Arima N, et al. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol. 2006;11(6):426–433. doi:10.1007/s10147-006-0601-617180510
   PubMedGoogle Scholar
• Yamashita H, Toyama T, Nishio M, et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 2006;8(4):R48. doi:10.1186/bcr153616869955
   PubMed Web of Science ®Google Scholar
• Bailey ST, Shin H, Westerling T, et al. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A. 2012;109(44):18060–18065. doi:10.1073/pnas.101885810923077249
   PubMed Web of Science ®Google Scholar
• Ungerleider NA, Rao SG, Shahbandi A, et al. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res. 2018;20(1):115. doi:10.1186/s13058-018-1044-530285883
   PubMed Web of Science ®Google Scholar
• Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer. 2020;6(2):98–110. doi:10.1016/j.trecan.2020.01.00732061310
   PubMed Web of Science ®Google Scholar
• Thewes V, Simon R, Schroeter P, et al. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer. Cancer Res. 2015;75(4):720–731. doi:10.1158/0008-5472.CAN-14-065225643697
   PubMed Web of Science ®Google Scholar
• Konduri SD, Medisetty R, Liu W, et al. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci U S A. 2010;107(34):15081–15086. doi:10.1073/pnas.100957510720696891
   PubMed Web of Science ®Google Scholar